MXPA05009640A - Tratamiento de condiciones intestinales con n-2,3,3-tetrametilbiciclo [2.2.1] heptan-3-amina. - Google Patents

Tratamiento de condiciones intestinales con n-2,3,3-tetrametilbiciclo [2.2.1] heptan-3-amina.

Info

Publication number
MXPA05009640A
MXPA05009640A MXPA05009640A MXPA05009640A MXPA05009640A MX PA05009640 A MXPA05009640 A MX PA05009640A MX PA05009640 A MXPA05009640 A MX PA05009640A MX PA05009640 A MXPA05009640 A MX PA05009640A MX PA05009640 A MXPA05009640 A MX PA05009640A
Authority
MX
Mexico
Prior art keywords
tetramethylbicyclo
amine
heptan
treatment
intestinal conditions
Prior art date
Application number
MXPA05009640A
Other languages
English (en)
Inventor
Devane John
Original Assignee
Agi Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Ltd filed Critical Agi Therapeutics Ltd
Publication of MXPA05009640A publication Critical patent/MXPA05009640A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

La presente invencion esta dirigida a metodos y formulaciones para reducir, prevenir y/o manejar incrementos anormales en la motilidad gastrointestinal y condiciones intestinales que provocan las mismas. Se incluyen los metodos de uso de N-2,2,3-tetrametilbiciclo-[2.1.1]heptan-2-amina y formulaciones que comprenden N-2,2,3-tetrametilbiciclo-[2.1.1]heptan-2-amina.
MXPA05009640A 2003-03-14 2004-03-12 Tratamiento de condiciones intestinales con n-2,3,3-tetrametilbiciclo [2.2.1] heptan-3-amina. MXPA05009640A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45452703P 2003-03-14 2003-03-14
PCT/IB2004/001134 WO2004080446A1 (en) 2003-03-14 2004-03-12 Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine

Publications (1)

Publication Number Publication Date
MXPA05009640A true MXPA05009640A (es) 2005-10-26

Family

ID=32990912

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009640A MXPA05009640A (es) 2003-03-14 2004-03-12 Tratamiento de condiciones intestinales con n-2,3,3-tetrametilbiciclo [2.2.1] heptan-3-amina.

Country Status (17)

Country Link
US (1) US20040209961A1 (es)
EP (1) EP1603544B1 (es)
JP (1) JP2006520379A (es)
AT (1) ATE375152T1 (es)
AU (1) AU2004218899A1 (es)
CA (1) CA2518385A1 (es)
CY (1) CY1108042T1 (es)
DE (1) DE602004009414T2 (es)
DK (1) DK1603544T3 (es)
ES (1) ES2294480T3 (es)
MX (1) MXPA05009640A (es)
NO (1) NO20054670L (es)
NZ (1) NZ542260A (es)
PL (1) PL1603544T3 (es)
PT (1) PT1603544E (es)
WO (1) WO2004080446A1 (es)
ZA (1) ZA200507159B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224284A1 (en) 2004-03-12 2007-09-27 John Devane Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof
US20060182818A1 (en) * 2005-02-17 2006-08-17 Ough Yon D Transdermal patch and treatment for pain and discomfort
US20060182819A1 (en) 2005-02-17 2006-08-17 Ough Yon D Soap scent patch and treatment for muscle spasm and pain
US20070108228A1 (en) * 2005-11-15 2007-05-17 Willam Kleyne Method and apparatus for flushing eyes and skin
US20080207766A1 (en) * 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
US8569381B2 (en) 2008-05-23 2013-10-29 Targacept, Inc. Combination therapy for the management of hypertension
CA3129729A1 (en) * 2009-09-29 2011-04-07 Novartis Ag Dosage regimen of an s1p receptor modulator
US8529914B2 (en) 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
KR102354954B1 (ko) 2016-04-04 2022-01-24 오메자 엘엘씨 어유 국소 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034079A (en) * 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
EP1019088B1 (en) * 1997-10-03 2003-02-12 Cary Medical Corporation Composition for the treatment of nicotine addiction containing mecamylamine and bupropion
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
WO2000033812A2 (en) * 1998-12-07 2000-06-15 Elan Corporation, Plc Transdermal patch for delivering volatile liquid drugs
US6734215B2 (en) * 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
PT1139743E (pt) * 1998-12-16 2006-06-30 Univ South Florida Formulacao de exo-s-mecamilamina e utilizacao em tratamento
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders

Also Published As

Publication number Publication date
ZA200507159B (en) 2008-03-26
AU2004218899A1 (en) 2004-09-23
WO2004080446A1 (en) 2004-09-23
PL1603544T3 (pl) 2008-03-31
CA2518385A1 (en) 2004-09-23
EP1603544B1 (en) 2007-10-10
CY1108042T1 (el) 2013-09-04
ES2294480T3 (es) 2008-04-01
ATE375152T1 (de) 2007-10-15
NO20054670D0 (no) 2005-10-11
DK1603544T3 (da) 2008-01-14
JP2006520379A (ja) 2006-09-07
DE602004009414T2 (de) 2008-07-24
US20040209961A1 (en) 2004-10-21
DE602004009414D1 (de) 2007-11-22
EP1603544A1 (en) 2005-12-14
NO20054670L (no) 2005-12-13
NZ542260A (en) 2009-03-31
PT1603544E (pt) 2008-01-22
WO2004080446B1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
NO20054670L (no) Behandling av intestinale tilstander med N-2,3,3-tetrametylbisyklo[2.2.1]-heptan-2-amid
EP1581169A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO NATURAL K CELLS
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
AU2003257937A8 (en) Methods and compositions for treatment of dermal conditions
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
WO2003101397A3 (en) Tetravalent dengue vaccines
EP1670450A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING LEVODOPA AND CARBIDOPA
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
IL174627A0 (en) Compositions and methods for treatment of burns
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
EP1711197A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR DISORDERS
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
NO20054346D0 (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
GB0324523D0 (en) Compositions and methods of treatment
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
UA85187C2 (en) 2-aminobenzoyl derivatives
EP1658075A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER AND OTHER PHYSIOLOGICAL STATES BASED ON THE MODULATION OF THE PPAR GAMMA PATH AND THE HERINE KINASE AXIS
EP1546326A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSORIASIS
EP1551386A4 (en) METHOD AND COMPOSITIONS FOR TREATING LUPUS WITH CLOFARABIN
EP1498145A4 (en) LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
IL151658A0 (en) Methods and compositions for the treatment or prevention of cardiovascular diseases

Legal Events

Date Code Title Description
FG Grant or registration